10 InterMune Analyst Ratings, Earnings, Dividends and Insider Trades | $ITMN | NASDAQ:ITMN | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact InterMune Company Profile (NASDAQ:ITMN) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for InterMune (NASDAQ:ITMN) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)Consensus Rating:Buy (Score: 2.50)Consensus Price Target: $35.27 (15.35% upside) Analysts' Ratings History for InterMune (NASDAQ:ITMN) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/6/2014RBC CapitalBoost Price TargetSector Perform$15.00 -> $28.00View 2/28/2014Jefferson ResearchUpgradeHold -> BuyView 2/27/2014Credit SuisseDowngradeOutperform -> NeutralView 2/26/2014UBS AGDowngradeMarket Perform$19.00 -> $43.00View 2/26/2014Goldman SachsBoost Price Target$40.00View 2/26/2014Canaccord GenuityBoost Price TargetBuy$22.00 -> $46.00View 2/26/2014Leerink SwannDowngradeOutperform -> Market Perform$41.00View 2/26/2014Jefferies GroupBoost Price Target$7.00 -> $20.00View 2/26/2014Credit SuisseDowngradeOutperform -> Neutral$15.00 -> $33.00View 2/25/2014Robert W. BairdBoost Price Target$44.00View 2/25/2014OppenheimerBoost Price Target$19.00 -> $42.00View 2/25/2014Wells Fargo & Co.Boost Price Target$43.00View 2/7/2014Summer StreetReiterated RatingPositiveView 1/14/2014Canaccord GenuityBoost Price TargetBuy$17.00 -> $22.00View 1/10/2014Stifel NicolausBoost Price TargetBuy$20.00 -> $23.00View 1/10/2014UBS AGBoost Price TargetBuy$15.00 -> $19.00View 11/1/2013Canaccord GenuityReiterated RatingBuy$17.00View 11/1/2013Stifel NicolausBoost Price TargetBuy$18.00 -> $20.00View 10/31/2013Leerink SwannBoost Price TargetOutperform$16.00 -> $17.00View 9/18/2013Canaccord GenuityReiterated RatingBuy$17.00View 9/18/2013Goldman SachsBoost Price Target$11.00 -> $12.00View 7/25/2013JMP SecuritiesBoost Price TargetMarket Outperform$15.00 -> $18.00View 7/25/2013Canaccord GenuityBoost Price TargetBuy$13.00 -> $17.00View 7/25/2013Stifel NicolausReiterated RatingBuy$17.00 -> $18.00View 7/25/2013Morgan StanleyReiterated RatingEqual WeightView 7/25/2013RBC CapitalBoost Price TargetSector Perform$12.00 -> $15.00View 7/16/2013Leerink SwannSet Price TargetOutperform$12.00 -> $16.00View 2/22/2013Stifel NicolausLower Price Target$17.00View 2/20/2013Robert W. BairdLower Price TargetOutperform$24.00 -> $23.00View 1/17/2013JMP SecuritiesUpgradeMarket Perform -> OutperformView 1/16/2013UBS AGUpgradeNeutral -> Buy$9.00 -> $15.00View 1/4/2013Stifel NicolausLower Price Target$19.00View 1/3/2013Robert W. BairdInitiated CoverageOutperform$24.00View 11/8/2012Canaccord GenuityUpgradeHold -> Buy$11.00 -> $13.00View 9/11/2012Robert W. BairdReiterated RatingOutperformView 9/4/2012Canaccord GenuityReiterated RatingHoldView 8/15/2012UBS AGCut EstimatesNeutral$8.50View 7/24/2012UBS AGReiterated RatingNeutralView 7/24/2012Stifel NicolausLower Price Target$23.00View 7/24/2012Canaccord GenuityDowngradeBuy -> Hold$11.00View 7/9/2012UBS AGReiterated RatingNeutralView 5/22/2012Goldman SachsReiterated RatingNeutralView 5/21/2012Canaccord GenuityReiterated RatingBuy -> PositiveView 5/9/2012Morgan StanleyLower Price Target$17.00 -> $15.00View 4/30/2012Canaccord GenuityReiterated RatingBuyView 4/29/2012Stifel NicolausLower Price TargetBuy$32.00 -> $31.00View 4/27/2012Brean CapitalLower Price Target$37.00 -> $33.00View 4/27/2012JMP SecuritiesDowngradeOutperform -> Market PerformView 4/12/2012UBS AGInitiated CoverageNeutral$13.50View 4/9/2012Brean CapitalLower Price Target$42.00 -> $37.00View 4/9/2012Canaccord GenuityReiterated RatingBuyView 4/9/2012Jefferies GroupLower Price Target$10.00 -> $9.00View 4/9/2012Leerink SwannReiterated RatingOutperformView 4/9/2012RBC CapitalDowngradeOutperform -> Sector Perform$23.00 -> $17.00View 4/9/2012Stifel NicolausLower Price TargetBuy$39.00 -> $32.00View 3/16/2012Jefferies GroupReiterated RatingUnderperform$10.00View 3/16/2012Canaccord GenuityReiterated RatingBuyView 3/12/2012Brean CapitalReiterated RatingBuyView (Data available from 3/6/2012 forward) Earnings History for InterMune (NASDAQ:ITMN)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare10/30/2013Q313($0.71)($0.61)$16.44 million$19.72 millionViewListenView 7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView 4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView 2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView 11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView 7/23/2012$0.10$0.01ViewN/AView 4/26/2012($0.70)($0.74)ViewN/AView 2/9/2012($0.71)($0.69)ViewN/AView 11/3/2011($0.72)($0.63)ViewN/AView 8/4/2011($0.62)($0.68)ViewN/AView 4/28/2011($0.78)($0.57)ViewN/AView 2/16/2011$0.64$3.34ViewN/AView (Data available from 1/1/2011 forward) Dividend History for InterMune (NASDAQ:ITMN)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for InterMune (NASDAQ:ITMN)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.95View 3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.00View 1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.00View 12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00View 10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View 8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.64View 8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.00View (Data available from 1/1/2013 forward) About InterMune InterMune, Inc. (InterMune), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, the Company began the commercial launch of Esbriet in Canada. June 19, 2012, the Company completed the divestiture of its worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by the Company under the tradename Actimmune. On June 19, 2012, the Company sold the rights of Actimmune (interferon gamma-1b) to Vidara Therapeutics International Limited. Headlines: (2/27) InterMune Slumps: ITMN Falls 14.9% in Session (2/25) InterMune Soars on IPF Study That May Support Approval (2/25) InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF) (2/6) InterMune (ITMN) Crumbles: Stock Falls by 6.8% (3/3) Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN (2/26) InterMune Inc. (ITMN) Soared To A New High On Phase 3 Study News (2/25) InterMune Inc. (ITMN) Has Soared To A New High On Study Results (3/5) Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: ITMN CUSIP: 45884X10 Key Metrics: Previous Close: $31.6450 Day Moving Average: $18.7274200 Day Moving Average: $15.4212 P/E Ratio: N/AP/E Growth: 0.71Market Cap: $2.744BCurrent Quarter EPS Consensus Estimate: $-2.53 EPS Additional Links: View ITMN on Google FinanceView ITMN on Yahoo FinanceView ITMN's Company Profile on ReutersSearch for InterMune Inc on Google InterMune (NASDAQ:ITMN) Chart for Thursday, March, 6, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.